Please assess the completion status of the following clinical trial:

Trial Title: Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, ≥ 18 years old.~2. Diagnosed with COVID-19, as evaluated by PCR test confirming infection with SARS-CoV-2, or suspected COVID-19 diagnosis based on radiological clinical findings.~3. Respiratory distress as evidenced by at least two of the following:~   * Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.)~  * Recording of SpO2 ≤ 90% or the patient is requiring supplemental oxygen to maintain an SpO2 ≥ 90%~  * Requiring supplemental oxygen~  * Diagnosis of mild, moderate, or severe ARDS by Berlin definition~4. A signed informed consent form from the patient or the patient's legal representative must be available.~Exclusion Criteria:~1. In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.~2. Patient has a do-not-resuscitate (DNR) or do-not-intubate (DNI) order in place~3. Patient has severe chronic obstructive pulmonary disease (COPD), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.).~4. Patient is on chronic immunosuppressive medication.~5. As a result of the medical review and screening investigation, the Principal Investigator considers the patient unfit for the study.~6. A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate).~7. Patient has known pregnancy or is currently breastfeeding.~8. Participation in another clinical trial (not including treatments for COVID-19 as approved by the FDA through expanded access or compassionate use).~9. Baseline QT prolongation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ampion (Type: EXPERIMENTAL): Ampion
- Standard of Care (Type: OTHER): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).